XZP-KM501

N/A

Report date: 2026/01/23 09:05:25

Base Information

Drug NameXZP-KM501
Drug Alias Name注射用重组抗HER2结构域II和结构域IV双特异性抗体-MMAE偶联物recombinant anti-HER2 domain II and domain IV bispecific antibody for injection-MMAE conjugate (Xuanzhu (Shijiazhuang) Biotechnology)XZP-KM501KM-501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Xuanzhu Kangming Biotechnology Co LtdXuanzhu (Shijiazhuang) Biotechnology Co LtdXuanzhu (HK) Biopharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A